

Posters at 2026 ESMO Congress

October 23–27, 2026

**All times CEST/CET (Please note that the time zone will switch from CEST to CET between 24 and 25 October 2026, due to the end of daylight saving time.)*



Dana-Farber
Cancer Institute

PRESENTATION

SPEAKER

SESSION/TIME

Friday, October 23, 2026

4303P Cell-free chromatin epigenomic profiling enables non-invasive subtyping of pancreatic cancer

Marc Eid, MD

Translational Research and Biomarkers
Hall 5 | 15:15-16:00

4305P Comprehensive plasma epigenomic profiling derived lineage states in mCRPC associate with 177Lu-PSMA-617 response and resistance

Praful Ravi, MB BChir, MRCP

Translational Research and Biomarkers
Hall 5 | 15:15-16:00

4404P Decoding tumor gene expression from circulating chromatin at single-gene resolution

Rashad Nawfal, MD

Translational Research and Biomarkers
Hall 5 | 15:15-16:00

4439P Divergent vascular-immune trajectories dictate disease control to dual PD-L1 and VEGFA blockade in PD-1 refractory melanoma

Giuseppe Tarantino, PhD

Translational Research and Biomarkers
Hall 5 | 15:15-16:00

4449P Paired-biopsy multi-omic analysis reveals target-independent mechanisms of antibody–drug conjugate (ADC) resistance in metastatic breast cancer (MBC)

Paolo Tarantino, MD

Translational Research and Biomarkers
Hall 5 | 15:15-16:00

2254P Wearable derived Physical Activity and Patient Reported Fatigue and Sleep Differ by Hot Flash Severity Levels During Initial Treatment Phase in LIBERTAS Trial

Alicia Morgans, MD, MPH

Metastatic Prostate Cancer
Hall 5 | 15:15-16:00

2265P Baseline and dynamic changes in circulating tumor (ct) DNA as correlates of intrinsic and acquired resistance to 177Lu-PSMA-617 (LuPSMA) in metastatic castration-resistant prostate cancer (mCRPC)

Alok Tewari, MD, PhD

Metastatic Prostate Cancer
Hall 5 | 15:15-16:00

2266P CONVERGE-01: Ac-225 Rosopitamab Tetraxetan (CONV01- α) in Patients (Pts) with Androgen Pathway Modulator Resistant Prostate Cancer (APMR)

Praful Ravi, MB BChir, MRCP

Metastatic Prostate Cancer
Hall 5 | 15:15-16:00

Posters at 2026 ESMO Congress

October 23–27, 2026

**All times CEST/CET (Please note that the time zone will switch from CEST to CET between 24 and 25 October 2026, due to the end of daylight saving time.)*



Dana-Farber
Cancer Institute

PRESENTATION

SPEAKER

SESSION/TIME

Friday, October 23, 2026 (continued)

3599P Plasma Proteomics Reveals the Biological Landscape of Tyrosine Kinase Inhibitors (TKI) Sensitivity in Metastatic Renal Cell Carcinoma

Liliana Ascione, MD

Renal Cancer
Hall 5 | 15:15-16:00

3601P Characterizing the long tail of somatic mutations in clear-cell renal cell carcinoma (ccRCC)

Eddy Saad, MD

Renal Cancer
Hall 5 | 15:15-16:00

3602P Clinical and transcriptomic correlates of primary resistance to nivolumab plus ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC)

Elio Ibrahim, MD

Renal Cancer
Hall 5 | 15:15-16:00

4743P Functional epigenomic liquid biopsy to guide treatment at EV/P resistance in metastatic urothelial carcinoma (mUC): Emerging role of ERBB3

Joaquim Bellmunt, MD, PhD

Urothelial Cancer
Hall 5 | 15:15-16:00

Saturday, October 24, 2026

594P Real-world eligibility for DESTINY-Breast11 (DB-11) neoadjuvant escalation criteria and outcomes of DB-11-eligible vs DB-11- ineligible patients with HER2-positive early breast cancer (HER2+ eBC)

Paolo Tarantino, MD

Breast Cancer, Early Stage
Hall 5 | 12:00-12:45

1796TiP BREnnA: Phase II/III randomised study of ZN-A-1041 or tucatinib (TUC), in combination with trastuzumab + capecitabine (HX), in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (HER2+ LA/mBC) with or without central nervous system (CNS) metastases

Nancy Lin, MD

HER2+ Breast Cancer
Hall 5 | 12:00-12:45

Posters at 2026 ESMO Congress

October 23–27, 2026

**All times CEST/CET (Please note that the time zone will switch from CEST to CET between 24 and 25 October 2026, due to the end of daylight saving time.)*



Dana-Farber
Cancer Institute

PRESENTATION

SPEAKER

SESSION/TIME

Saturday, October 24, 2026 (continued)

1872P Expert consensus on management of ribociclib (RIB)-associated liver-related adverse events (AEs) in HR+/HER2– breast cancer: a modified Delphi panel

Erica Mayer, MD, MPH

HER2+ Breast Cancer
Hall 5 | 12:00-12:45

1873P Gedatolisib (Ged) vs Other Regimens Post-CDK4/6i and Endocrine Therapy (ET) in PIK3CA Wild-Type (WT) HR+/ HER2- Advanced Breast Cancer (aBC): A Network Meta-Analysis (NMA)

Sara Tolaney, MD, MPH

HER2+ Breast Cancer
Hall 5 | 12:00-12:45

1885TiP KANDELA-302: A Phase 3, Global, Open-Label, Randomized Study of the Selective CDK4 Inhibitor BGB-43395 + Letrozole vs CDK4/6 Inhibitors (CDK4/6i) + Letrozole for First-Line (1L) Treatment (Tx) of Advanced or Metastatic HR+/HER2– Breast Cancer (BC)

Sara Tolaney, MD, MPH

HR+ Breast Cancer
Hall 5 | 12:00-12:45

4668P ASCENT-03: Real-World (RW) External Control Arm (ECA) Analysis of First-Line (1L) Sacituzumab Govitecan (SG) vs Treatment of Physician's Choice (TPC) in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC)

Ana Garrido-Castro, MD

Triple Negative Breast Cancer
Hall 5 | 12:00-12:45

708P Clinical and molecular characteristics of leptomeningeal disease in metastatic breast cancer patients – a prospective observational registry study

Angelika Starzer, MD, PhD

CNS Tumors
Hall 5 | 12:00-12:45

1969P Clinical activity of tislelizumab in PD1 mRNA high advanced solid tumors: SOLTI-1904 ACROPOLI phase II trial

Elia Segui, MD

Investigational Immunotherapy
Hall 5 | 12:00-12:45

1998P Germline IL7 variant confers organ-specific susceptibility to thyroid and joint immune-related adverse events independent of cancer type and treatment regimen

Mustafa Saleh, MD

Investigational Immunotherapy
Hall 5 | 12:00-12:45

Posters at 2026 ESMO Congress

October 23–27, 2026

**All times CEST/CET (Please note that the time zone will switch from CEST to CET between 24 and 25 October 2026, due to the end of daylight saving time.)*



Dana-Farber
Cancer Institute

PRESENTATION

SPEAKER

SESSION/TIME

Saturday, October 24, 2026 (continued)

2114P Recurrence of Checkpoint Inhibitor–Induced Immune-Related Adverse Events After Tumor-Infiltrating Lymphocyte Therapy in Metastatic Melanoma

Karam Khaddour, MD,
MS

Melanoma
Hall 5 | 12:00-12:45

2140TiP LNS-103: A randomized, controlled trial of LNS8801 with or without pembrolizumab in patients with immunotherapy-refractory melanoma

Justine Cohen, DO

Melanoma
Hall 5 | 12:00-12:45

Monday, October 26th, 2026

1559P Neoadjuvant and adjuvant pembrolizumab (pembro) for locally advanced head and neck squamous cell carcinoma (LA HNSCC): post-operative residual viable tumor (RVT) in the KEYNOTE-689 trial

Robert Haddad, MD

Head and Neck Cancer, excluding thyroid
Hall 5 | 12:00-12:45

1582P RGT-61159, an Oral MYB Splicing Modulator, Demonstrates Exposure-Dependent Target Engagement and Early Clinical Activity in Advanced Adenoid Cystic Carcinoma

Glenn Hanna, MD

Head and Neck Cancer, excluding thyroid
Hall 5 | 12:00-12:45

3811P Biomarkers Associated With Response to the CAR-T Cell Therapy LB2102 in Subjects with SCLC or LCNEC

Jacob Sands, MD

Small Cell Lung Cancer
Hall 5 | 12:00-12:45

2686P RAS2mt Non-small cell lung cancer (NSCLC) defines a distinct subset of RASmt NSCLC

Kristi Beshiri, MD, PhD

Non-small Cell Lung Cancer, Metastatic
Hall 5 | 12:00-12:45

4175P Immune checkpoint inhibitors in NUT carcinoma: an analysis from the International NUT Carcinoma Registry

Kristi Beshiri, MD, PhD

Thoracic Malignancies, Other
Hall 5 | 12:00-12:45